FR3015523B1 - MOLECULAR SIGNATURE OF ACTINIC LENTIGO - Google Patents

MOLECULAR SIGNATURE OF ACTINIC LENTIGO Download PDF

Info

Publication number
FR3015523B1
FR3015523B1 FR1363204A FR1363204A FR3015523B1 FR 3015523 B1 FR3015523 B1 FR 3015523B1 FR 1363204 A FR1363204 A FR 1363204A FR 1363204 A FR1363204 A FR 1363204A FR 3015523 B1 FR3015523 B1 FR 3015523B1
Authority
FR
France
Prior art keywords
genes
relates
molecular signature
signature
actinic lentigo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1363204A
Other languages
French (fr)
Other versions
FR3015523A1 (en
Inventor
Olivier De Lacharriere
Stephanie Nouveau
Francoise Bernerd
Christine Duval
Emilie Warrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to FR1363204A priority Critical patent/FR3015523B1/en
Publication of FR3015523A1 publication Critical patent/FR3015523A1/en
Application granted granted Critical
Publication of FR3015523B1 publication Critical patent/FR3015523B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

La présente invention concerne une signature moléculaire du lentigo actinique, comprenant les gènes HOXD10, HOXD11, PITX2, ZIC2, CYP39A1, SLC1A6 et TRAM1L1, et diverses applications de cette signature. L'invention concerne notamment une méthode de caractérisation d'une tache pigmentaire apparente chez un être humain, comprenant la comparaison des niveaux d'expression, dans des échantillons de peau issue de ladite tache et de peau adjacente non lésée, des gènes. L'invention concerne également une méthode de prédiction, des méthodes d'évaluation de l'efficacité d'un traitement des taches pigmentaires, des méthodes cosmétiques et thérapeutiques de traitement des taches pigmentaires, ainsi que divers modulateurs desdits gènes et leur utilisation.The present invention relates to a molecular signature of actinic lentigo, comprising the genes HOXD10, HOXD11, PITX2, ZIC2, CYP39A1, SLC1A6 and TRAM1L1, and various applications of this signature. The invention relates in particular to a method for characterizing an apparent pigment spot in a human being, comprising comparing the levels of expression, in samples of skin originating from said spot and of adjacent non-injured skin, of the genes. The invention also relates to a prediction method, methods for evaluating the effectiveness of a treatment for pigment spots, cosmetic and therapeutic methods for treating pigment spots, as well as various modulators of said genes and their use.

FR1363204A 2013-12-20 2013-12-20 MOLECULAR SIGNATURE OF ACTINIC LENTIGO Expired - Fee Related FR3015523B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1363204A FR3015523B1 (en) 2013-12-20 2013-12-20 MOLECULAR SIGNATURE OF ACTINIC LENTIGO

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1363204 2013-12-20
FR1363204A FR3015523B1 (en) 2013-12-20 2013-12-20 MOLECULAR SIGNATURE OF ACTINIC LENTIGO

Publications (2)

Publication Number Publication Date
FR3015523A1 FR3015523A1 (en) 2015-06-26
FR3015523B1 true FR3015523B1 (en) 2020-05-29

Family

ID=50976695

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1363204A Expired - Fee Related FR3015523B1 (en) 2013-12-20 2013-12-20 MOLECULAR SIGNATURE OF ACTINIC LENTIGO

Country Status (1)

Country Link
FR (1) FR3015523B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913578A2 (en) * 2008-05-14 2017-06-06 Dermtech Int diagnosis of melanoma and solar lentigo by nucleic acid analysis
EP2699221B1 (en) * 2011-04-22 2017-02-08 L'Oréal Molecular signature for skin pigment spots, which is combined with the extracellular matrix

Also Published As

Publication number Publication date
FR3015523A1 (en) 2015-06-26

Similar Documents

Publication Publication Date Title
EA201590630A1 (en) METHODS OF TREATMENT AND DIAGNOSTICS ASSOCIATED WITH LYZYLOXIDE-LIKE PROTEIN 2 (LOXL2)
EA201201650A1 (en) HUMAN BINDING MOLECULES THAT HAVE KILLING ACTIVITY AGAINST STAFILOCCUS AND THEIR APPLICATION
EA201790195A1 (en) METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS
EA201890619A1 (en) COMPOSITIONS of iRNA LIGANDA 1 PROTEIN PROGRAMMED DESTRUCTION OF CELLS 1 (PD-L1) AND METHODS OF THEIR APPLICATION
MA40939A (en) USING THE SIZE OF ACELLULAR DNA FRAGMENTS TO DETERMINE VARIATIONS IN THE NUMBER OF COPIES
EA201791167A1 (en) METHODS AND COMPOSITIONS FOR SWITCHING RADIOACTIVE ISOTOPOM FOR BIOLOGICAL PREPARATIONS
EA201992252A1 (en) LOGOMETRIC METHODS OF VISUALIZATION OF FLUORESCENCE
MA38400A1 (en) Bispecific fc molecules
BR112016008694A2 (en) METHODS FOR PREDICTING THE REACTION OF PATIENTS WITH ASTHMA, FOR PREDICTING THE ABILITY TO REACT IN PATIENTS WITH ASTHMA, FOR IDENTIFYING PATIENTS WITH ASTHMA, FOR TREATMENT OF PATIENTS WITH ASTHMA AND FOR TREATMENT OF ASTHMA, USE OF A KIT AND KIT
EA201690111A1 (en) IMIDAZOPIRAZINE INHIBITORS OF SYK THYROZINKINASE
BR112015022934A2 (en) neuroactive steroids, compositions, and use thereof
EA201691079A1 (en) COMBINED THERAPY FOR THE TREATMENT OF ONCOLOGICAL DISEASE
BR112016018205A8 (en) methods of treating alzheimer's disease, patient selection, patient identification, prediction, therapeutic efficacy optimization, kit, agent use and in vitro agent use
EA201390506A1 (en) POLYPEPTIDES THAT BIND THE COMPONENT C5 OF THE HUMAN COMPLEX
DE602005016800D1 (en) HIF-prolyl hydroxylase ACTIVITY TEST
BR112018012255A2 (en) method to treat cancer
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
BR112014002363A2 (en) src 2 homology domain agonists containing protein tyrosine phosphatase - 1 and treatment methods using the same
MA44922A1 (en) Antibody
AR080361A1 (en) IDENTIFICATION, EVALUATION AND THERAPY OF CANCERES WITH INNATE RESISTANCE OR ACQUIRED TO QUINASA INHIBITORS OF ANAPLASIC LYMPHOMA (ALK)
ATE472998T1 (en) CATIONIC LIPOSOMAL PREPARATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
MX2018014047A (en) Stromal gene signatures for diagnosis and use in immunotherapy.
BR112014024487A2 (en) methods to increase the effectiveness of cd37-based therapy
EA201990730A1 (en) RNA BIOMARKERS FOR HEREDITARY ANGIONEUROTIC Edema
NZ729773A (en) Biomarkers for disease progression in melanoma

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 7

ST Notification of lapse

Effective date: 20210805